We are live on ! Find out more
INSY

Insys Therapeutics, Inc.
INSY

Delisted

INSY was delisted on the 18th of June, 2019.

99 hedge funds and large institutions have $372M invested in Insys Therapeutics, Inc. in 2014 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 36 increasing their positions, 35 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

144% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 9

126% more call options, than puts

Call options by funds: $4.81M | Put options by funds: $2.13M

89% more capital invested

Capital invested by funds: $197M → $372M (+$175M)

15% more funds holding

Funds holding: 8699 (+13)

3% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 35

Holders
99
Holders Change
+13
Holders Change %
+15.12%
% of All Funds
2.86%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.09%
New
22
Increased
36
Reduced
35
Closed
9
Calls
$4.81M
Puts
$2.13M
Net Calls
+$2.68M
Net Calls Change
+$2.53M
Name Holding Trade Value Shares
Change
Change in
Stake
EMFAT
101
Emerald Mutual Fund Advisers Trust
Pennsylvania
-$6.09M -398,586 Closed
EA
102
Emerald Advisers
Pennsylvania
-$4.58M -354,726 Closed
CIP
103
Convergence Investment Partners
Florida
-$675K -52,350 Closed
ZIM
104
Zacks Investment Management
Illinois
-$438K -33,930 Closed
Jane Street
105
Jane Street
New York
-$338K -26,232 Closed
Massachusetts Financial Services
106
Massachusetts Financial Services
Massachusetts
-$257K -19,950 Closed
SGAM
107
Smith Group Asset Management
Texas
-$68K -5,271 Closed
HF
108
Hoxton Financial
West Virginia
-$5K -354 Closed

INSY Hedge Fund Activity: Q1 2014 in Review

99 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q1 2014, worth a combined $372M — up 89% from $197M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new INSY positions and 9 closed out — a net gain of 13 holders — while 36 added to existing stakes and 35 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $42.4M. The largest seller was BlackRock Advisors, cutting an estimated $13.3M.

  • 99 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q1 2014, up from 86 in Q4 2013.
  • Funds reported $372M of Insys Therapeutics, Inc. stock for Q1 2014, up 89% quarter-over-quarter.
  • 22 funds opened new Insys Therapeutics, Inc. positions in Q1 2014 and 9 closed out, a net change of +13 holders.
  • The largest Insys Therapeutics, Inc. buyer in Q1 2014 was Fidelity Investments, an estimated $42.4M added.
  • The largest Insys Therapeutics, Inc. seller in Q1 2014 was BlackRock Advisors, an estimated $13.3M sold.

Based on aggregated 13F filings for Q1 2014.